Teplizumab in Pediatric Stage 2 Type 1 Diabetes

The purpose of this study is to assess the safety and PK of teplizumab in participants with Stage 2 type 1 diabetes who are <8 years of age.

Inclusion Criteria:Participant is a male or female 0 to < 8 years of age, inclusive, at Day 1Participant has Stage 2 T1D (two T1D-related autoantibodies and dysglycemia)Exclusion Criteria:Participant has any autoimmune disease other than T1D with the exception of stable thyroid or celiac diseaseHas an active infection and/or feverHas a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).Has any condition that, in the opinion of the Investigator, would interfere with the study conduct or the safety of the participant.